.08 semaglutide Could This Be the New Ozempic? Less Than Two Years After

: Antibody-Drug Conjugate (ADC) CDMO Services Peptide-Drug Conjugate CDMO Services Oligonucleotide Conjugate CDMO Services Protein Conjugate CDMO Services Others : Pharmaceutical Companies Biotechnology Companies Research Institutes Others : North America Europe Asia-Pacific South America Middle East & Africa : Lonza Catalent Samsung Biologics WuXi AppTec AGC Biologics Axplora Sterling Pharma Solutions BSP Pharmaceuticals S.p.A

Current Neuropharmacology, 16(7), 847855

Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): randomized phase II trial results

Diabetic retinopathy or active retinal disease

People with type 2 diabetes have an 84% higher baseline risk of developing pancreatitis compared to the general population

Some weight loss treatments aim to correct hormonal imbalances that contribute to weight gain